Back to Journals » Cancer Management and Research » Volume 13
microRNA-877 Inhibits Malignant Progression of Colorectal Cancer by Directly Targeting MTDH and Regulating the PTEN/Akt Pathway [Retraction]
Zhang L, Li C, Cao L, et al. Cancer Manag Res. 2019;11:2769–2781.
The Editor and Publisher of Cancer Management and Research wish to retract the published article. Concerns were raised over alleged image duplication in Figures 2D, 3B and 6E with similar images from unrelated articles, specifically:
- Figure 2D, panel HCT-116 miR-877 mimics appears to have been duplicated with a similar image in Figure 2G from Ji et al, 2017 (https://doi.org/10.3892/mmr.2017.7332) and Figure 2D from Hu et al, 2018 (https://doi.org/10.3727/096504018X15154112497142).
- Figure 3B, panel HCT-116 miR-877 mimics appears to have been duplicated with a similar image in Figure 2C from Zhou et al, 2019 (DOI: 10.3892/etm.2019.7676).
- Figure 6E, panel SW-480 miR-877 mimics+pcDNA3.1 appears to have been duplicated with a similar image in Figure 5C from Zhou et al, (DOI: 10.3892/etm.2019.7676).
The authors responded to our queries but were unable to provide a satisfactory explanation for the alleged duplication and could not provide satisfactory original data for their study. The Editor advised for the article to be retracted.
Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.